CD27- IgD- B cell memory subset associates with inflammation and frailty in elderly individuals but only in males

Tapio Nevalainen 1,3,4*, Arttu Autio 1,3,4, Laura Kummola 1, Tanja Salomaa 1, Ilkka Juntila 1,5, Marja Jylhä 2,3 and Mikko Hurme 1,3

Abstract

**Background:** Immunosenescence, i.e. the aging-associated decline of the capacity of the immune system, is characterized by several distinct changes in the number and functions of the immune cells. In the case of B cells, the total number of CD19+ B cells is lower in the blood of elderly individuals than in the younger ones. CD19+ B cell population contains several subsets, which are commonly characterized by the presence of CD27 and IgD molecules, i.e. naïve B cells (CD27- IgD+), IgM memory (CD27+ IgD+), switched memory (CD27+ IgD-) and late memory (CD27- IgD-). This late memory, double negative, population represents cells which are nondividing, but are still able to produce inflammatory mediators and in this way maybe contributing to the aging-associated inflammation, inflammaging. Here we have focused on the role of these B cell subsets in elderly individuals, nonagenarians, in the regulation of inflammation and inflammation-associated decline of bodily functions. As the biological aging process demonstrates gender-specific characteristics, the analyses were performed separately in males and female.

**Results:** A subcohort of The Vitality 90+ study (67 nonagenarians, 22/45 males/females and 40 young controls, 13/27 males/females) was used. Flow cytometric analysis indicated that the total percentage of the CD19+ cells was ca. 50% lower in the nonagenarians than in the controls in both genders. The proportions of these four B cell subsets within the CD19+ populations were very similar in young and old individuals. Thus, it seems that the aging-associated decline of the total CD19+ cells affects similarly all these B cell subsets. To analyze the role of these subsets in the regulation of inflammation, the correlation with IL-6 levels was calculated. A significant correlation was observed only with the percentage of CD27- IgD- cells and only in males. As inflammation is associated with aging-associated functional performance and frailty, the correlations with the Barthel index and frailty score was analyzed. Again, only the CD27- IgD- population demonstrated a strong male-specific correlation.

**Conclusions:** These data show that the CD27- IgD- B cell subset demonstrates a strong pro-inflammatory effect in nonagenarians, which significantly associates with the decline of the bodily functions. However, this phenomenon is only observed in males.

**Keywords:** Immunosenescence, B cell, Aging, Frailty

* Correspondence: tapio.nevalainen@tuni.fi
1 Faculty of Medicine and Health Technology, Tampere University, FI-33014 Tampere, Finland
3 Gerontology Research Center, Tampere University, Tampere, Finland

Full list of author information is available at the end of the article

© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background

The impact of aging on the function of the immune system is commonly called immunosenescence. Both the changes at the level of individual cells of the immune system as well as the clinical diseases associated with its presence are relatively well characterized (for recent reviews, see [1, 2]). The immune system contains several functional entities such as innate/non-adaptive immune response, inflammation, and adaptive (B and T cell mediated) immune response and all of these are clearly affected by aging.

One distinct component of immunosenescence is the increased rate of inflammation, often called inflammaging (reviewed in [3]). It is a chronic, sterile, low grade inflammation that is manifested by an increase of several markers of inflammation in the blood of elderly individuals. It is currently recognized as the main driving force of the aging-associated phenotypic changes and a significant risk factor for the aging-associated diseases (reviewed in [4]). Although these adverse effects of inflammaging are now better characterized, the factors inducing inflammaging or modulating its activity are still, at least partly, unknown. These factors could be categorized as follows: i) infectious agents not eliminated by the aging immune system ii) cellular debris released from an ongoing degenerative disease (in some cases this would indicate reverse causality, i.e. inflammation is a consequence rather than cause of this disease process) iii) environmental and life-style factors iv) aging-associated increased or activity of a given cell type having a pro-inflammatory activity.

There are four relatively well-characterized CD19+ cell subtypes in the human peripheral blood i.e. naïve (CD27-IgD-), IgM memory (CD27+ IgD-), switched memory (CD27+ IgD+) and late memory (CD27- IgD-) [5]. Although there are obvious inter-individual differences and variation in the analysis methods it seems that the total percentage of CD19+ cells is decreased in aged individuals and consequently, also the number of the cells in these subsets is lower [5]. It is very likely that the activity of the CD27-IgD- subset contributes to inflammmaging as it has the characteristics of the senescence-associated secretory phenotype (SASP) (nondividing, metabolically active and secreting proinflammatory cytokines) (reviewed in [6]). SASP phenotype in the cells of the immune system is probably a consequence of the general cellular senescence, which is known to be involved in the pathogenesis of many common diseases (e.g. diabetes, hypertension, tumorigenesis) (reviewed in [7]). In the case of immune/inflammatory diseases increased SASP activity has been observed in several infections and autoimmune diseases (reviewed in [8]).

In this study, we analyzed the significance of the CD27-IgD- B cells on the development of the serious aging-associated condition, i.e. frailty.

Methods

Study population

The study population consisted of 67 nonagenarians (22 males, 45 females) and 40 young controls (age 19–29 years, 13 males, 27 females) who were participants in the Vitality 90+ study, an ongoing population-based study involving individuals aged 90 years or older and living in the city of Tampere, Finland. The recruitment and characterization of the participants in this cohort have been characterized [9, 10]. The study protocol was approved by the ethics committee of the city of Tampere (1592/403/1996) and the study was conducted according to the principles expressed in the declaration of Helsinki.

Collection of the blood samples and purification of peripheral blood mononuclear cells (PBMC) have recently been published in detail [11].

Flow cytometry

After thawing, samples were washed with 1% fetal bovine serum (FBS) in phosphate-buffered saline (PBS) and incubated with Human BD Fc Block™ (BD, Franklin Lakes, NJ, US) for 10 min at room temperature. Cells were then surface stained with a mixture of the following mouse anti-human antibodies (all eBioscience™ from Thermo Fisher Scientific, Waltham, MA, US): FITC-IgD (clone 1A6-2), PE-CD43(clone eBio84-3C1), PerCP-Cy5.5-CD19 (clone HIB19), PE-Cy7-CD27 (clone C323), APC-eFluor780-CD3 (clone UCHT1), APC-eFluor-CD14 (clone 61D3), APC-eFluor780-CD56 (clone CMSSB) and APC-CD20 (clone 2H7). After 20 min at 4 °C, the cells were washed twice with 1% FBS in PBS and samples were analyzed with FACSCanto II (BD). Further analysis was performed with FlowJo software (Ashland, OR, US). Gating was based on fluorescence minus one controls with slight adjustments according to individual variation. Debris and clearly apoptotic cells were excluded by FSC/SSC gating, but due to limitations in flow cytometer detector availability, staining for viability and CD45 was not performed. The PE-CD43 and APC-CD20 antibodies were included in the original antibody mixture for purposes outside the scope of this report.

Assessment of functional performance and frailty

Physical performance in everyday life was assessed using the 10-item Barthel index [12]. It includes the activities required for daily living (such as mobility, dressing, feeding, toilet use, bowel and bladder control). Each task was scored individually (0–10) and the total score of 100 indicates maximum independence and the score 0 reflects total dependence. The frailty index was calculated as described in detail by Fried et al. [13]. The criteria included 1) mini-mental state examination (MMSE) score 2) weight loss 3) self-reported fatigue 4) hand grip strength
5) mobility. The sum of these criteria gives the final index (min 0, max 5).

**IL-6 quantification**
The plasma interleukin 6 (IL-6) concentration was measured using the Pelikine human IL-6 ELISA kit (Sanguin, Amsterdam, The Netherlands).

**Statistical analysis**
The differences in proportions of CD19+ cells, in proportions of B cell subsets, and plasma IL-6 levels between nonagenarian group and young group were analyzed using Mann-Whitney U test. Spearman’s Rank-Order correlation was used to test the association of B cell subsets with plasma IL-6 levels, Barthel index and Frailty index. All statistical analyses were performed using IBM SPSS Statistics version 25.

**Results**
As reported in previous studies, the percentage of CD19+ B cells was clearly reduced in the elderly individuals as compared to the young controls. In the flow-cytometric analysis this was observed both by gating directly the CD19+ cells and after first gating out the CD3+, CD14+ and CD56+ cells. This reduction was slightly stronger in females ($p < 0.001$, using both gating strategies) than in males ($p = 0.002$ and $p = 0.011$) with direct gating and with gating out the dump channel (CD3, CD56 and CD14, respectively) (Fig. 1).

The proportions of the CD27- IgD-, CD27- IgD+, CD27+ IgD- and CD27+ IgD+ subpopulations are shown in Fig. 2. It shows that the naïve B cells (CD27-IgD+) form the majority in both young and old individuals and in both genders.

In the case of the three memory cell populations the general pattern of the proportions (Fig. 2) indicates that age and gender associated differences are minor. However, in females the higher proportion of CD27-IgD- cells ($p = 0.009$) and lower proportions of CD27+ IgD- cells ($p = 0.002$) and CD27- IgD- cells ($p = 0.022$) in nonagenarians as compared to controls were statistically significant. There was no significant aging associated difference in the CD27+ IgD- subpopulation. In the case of males, all age associated differences in the CD19+ subpopulation proportions were non-significant ($p = 0.113$, $p = 0.159$, $p = 0.057$ and $p = 0.139$ for CD27+ IgD-, CD27+ IgD+, CD27- IgD+ and CD27- IgD-, respectively).

Taken together, the data this far shows that aging does not have a profound effect on the relative proportions of these B cell subsets; as the total number of B cells is clearly reduced (ca. 50%, see Fig. 1.) it can be concluded that also the total cell number of the four subsets are reduced in the aged individuals. To confirm that age associated reduction in CD19+ cells affects all CD19+ subpopulations, cell numbers, from which the subpopulation proportions were calculated, were also examined. The distributions of the cell numbers of the CD19+ subpopulations are shown in Fig. 1 (panels C and D). These distributions are clearly similar in shape over gender and age. Only notable difference seems to be the overall magnitude of the cell numbers over the age, that is explained by the difference in the number of CD19+ cells between nonagenarians and young individuals. This concludes that the age associated decrease in the CD19+ cells affects all the studied CD19+ subpopulations.

To examine the functional role of these B cell subsets, their associations with the serum levels of IL-6, i.e. the prototype proinflammatory cytokine, were analyzed. Figure 3 demonstrates that IL-6 levels were increased in the elderly individuals, both in males ($p = 0.007$) and females ($p = 0.010$). The data shown in Table 1 demonstrate that these levels correlated only with the proportion of the CD27- IgD- subset but only in males; thus, in males, the higher proportion of the cells were CD27- IgD-, the higher the plasma IL-6 level was.

Aging is associated with a decline of the physical capacity in everyday life as well as increased vulnerability to endogenous and exogenous stressors. These changes are commonly quantitated using the Barthel and frailty indices, respectively. As inflammation is known to be associated with these parameters, we next analyzed the correlations of the B cell subsets with these indices. Table 2 shows that both of these indices correlate significantly only with the percentage of the CD27- IgD- population but only in males. Thus, this cell population seems to be involved in the mechanisms leading to the decline of functional capacity (negative correlation with the Barthel index) and increasing frailty.

Gender did not have a significant effect on these indices (Barthel, mean 83 in females and 79 in males, frailty mean 2.1 in males and 2.5 in females). The original frailty index (min 0, max 5) was also modified to a 3 step index (0–1 = non-frail, 2–3 = pre-frail, 4–5 = frail). The number of nonagenarian male individuals in each frailty group were 3, 8 and 11 for the non-frail, pre-frail and frail, respectively, and the number of nonagenarian female individuals in each frailty group were 2, 20 and 17 for the non-frail, pre-frail and frail, respectively. The number of nonagenarian male individuals in each frailty group were 3, 8 and 11 for the non-frail, pre-frail and frail, respectively, and the number of nonagenarian female individuals in each frailty group were 2, 20 and 17 for the non-frail, pre-frail and frail, respectively. The data shown in Fig. 4 shows that the percentage of the CD27- IgD- is ca. 3 times higher in the frail males than in the non-frails.

**Discussion**
The findings reported here are in line with the previous data demonstrating that the CD27- IgD- B cell memory subset has a pro-inflammatory character. However, two novel aspects were observed. Firstly, its effect was so strong that there was a clear correlation with its
increased proportion and the aging-associated decline of the physical capacity of the elderly individuals. Secondly, its effect was restricted to males.

As stated above, the CD19+ CD27- IgD- cells have a clear SASP phenotype, and are extensively characterized [5]. They are able to produce pro-inflammatory cytokines (tumor necrosis factor (TNF), IL-6, interleukin 8 (IL-8)) and contain typical inflammatory micro-RNAs. Obviously, they are already in a pre-activated stage. They also contribute to a functionally important parameter of immunosenescence, i.e. reducing the efficacy of vaccinations (at least in the case of influenza virus) [14]. The data shown here that this cell type has a deleterious effect on the physiological reserves of the elderly individuals, as quantitated with the frailty index. It is unlikely, that a cell type with such a low frequency (less than 5% of the total PBMC number) would alone be responsible for such an effect. Thus, it is feasible that increase or activity of additional cell types with SASP phenotype would contribute to the observed effect. In fact, we addressed this question by analyzing the role of CD8+ CD28- T lymphocytes, i.e. a well-defined cell type with the SASP phenotype [15], in the same way as described here. However, the frequency of these cells did not correlate with any of the parameters used in this study (data not shown).

It has been shown that frailty is associated with several markers of inflammation, [16]. As frailty is a complex phenotype affecting many organs and tissues and probably also via various molecular pathways, it is obvious that it is not induced by a single molecule. In this study,
we used IL-6 levels to quantitate the inflammation. IL-6 levels were associated much more weakly with the frailty index than the percentage of CD27- IgD- cells (data not shown), underlining the importance of yet uncharacterized factors in the pathogenesis of frailty.

The pro-inflammatory effect of the CD27- IgD- B cells was restricted to males. This is in line with our previous data [17]. In that study, we examined the correlation of IL-6 levels with transcriptomic and epigenetic changes in PBMCs of nonagenarians. In males, there were several
transcripts correlating with IL-6 levels while in females there were none. These transcripts were involved in processes that were linked to inflammatory pathways. Thus, it seems likely, that the effect of the IL-6 component of inflammaging is gender-dependent. Obviously, this does not mean that all the effects of the CD27- IgD- cells would be restricted to males.

In this study, we used two indices, Barthel and frailty, to quantitate the aging-associated biological and functional deficiencies. Although the measured parameters or the questions asked in the calculation of these indices are different, they correlated significantly. This is not unexpected, as it is likely that decline of the biological capacity, i.e. frailty, probably leads to the functional deficiencies quantitated with the Barthel index. Although inflammaging associates with several disease states and pathogenic mechanisms (see above), it is probable that it is not functionally uniform entity, i.e. different forms of inflammaging have different targets. Individual analysis of the different assessment steps in the calculation of the frailty index might be informative in this respect. We observed that the CD27- IgD- proportion correlated very significantly with the muscle strength (the handgrip test), but only weakly with the cognitive status (MMSE test, data not shown). Thus, it is possible that the CD27-IgD- population associated inflammation affects preferentially the physical capacity (muscles, circulation).

The elderly individuals used in this study were nonagenarians, i.e. the biological aging process had progressed very far. It would be of interest to analyze the role of this CD27-IgD- cell type associated phenomena on the earlier stages of physical aging, e.g. at the age of 60–80 years, preferably in a follow-up setting. Unfortunately, such samples are not available in the Vitality 90+ cohort. A positive influence observed in these “younger” ones would maybe indicate that the effect of these CD27-IgD- cells is more general and would influence the pace of the decline of the physical functions. The reverse results, such that the findings would be restricted to nonagenarians, could be explained with differential inflammatory mediator profiles; the composition of the factors in the pool of the inflammatory mediators could be different between these age groups. However, in this study we used IL-6 as the marker of inflammation, i.e. the cytokine showing the male-restricted activity [17], while IL-1 levels, although increased in the nonagenarians, did not associate with the proportion of the CD27- IgD- cells (data not shown). Moreover, the central role of IL-6 in the present observations is further emphasized by its role as a biomarker, even an inducer of sarcopenia, (reviewed in [18]).

As for the male-specificity of the observed associations, it was quite surprising that the observed correlations between the proportion of CD27-IgD- cells and frailty and Barthel indexes were restricted to males. At

**Table 1** Spearman correlation of the plasma IL-6 levels (pg/ml) with the proportions of the B cell subsets in nonagenarians (22 males, 39 females)

| B cell subset | gender | correlation coefficient | p-value |
|---------------|--------|-------------------------|---------|
| CD27- IgD-    | male   | 0.666                   | < 0.001 |
|               | female | 0.183                   | 0.265   |
| CD27- IgD+    | male   | -0.253                  | 0.256   |
|               | female | -0.150                  | 0.362   |
| CD27+ IgD+    | male   | -0.217                  | 0.331   |
|               | female | 0.004                   | 0.982   |
| CD27+ IgD-    | male   | -0.300                  | 0.175   |
|               | female | 0.015                   | 0.926   |

Correlation coefficient and significance of statistically significant associations are indicated in boldface.
The molecular/cellular background of this phenomenon is open and can only be speculated. Firstly, it is obvious that the number of the CD27- IgD- cells as such is not decisive, i.e. the proportion of these cells is even somewhat higher in females than in males (Fig. 2). Secondly, the production and effect of the proinflammatory cytokines could have a role. In this study, we used IL-6 as the indicator. Its serum levels were ca. two times higher in nonagenarian males than in females (Fig. 3), and correlated significantly with the proportion of the CD27- IgD- cells but only in males. Moreover, IL-6 levels demonstrated a weak correlation with the frailty index \( (p < 0.05 \text{ in males}) \). We have previously shown that in male PBMCs IL-6 is a more potent activator than in female cells \[ 17 \]. Thus, taken together, it is likely that both the IL-6 producer cell type, as well as the

| B cell subset | gender | \( r \) (Barthel index) | \( p \)-value (Barthel index) | \( r \) (Frailty index) | \( p \)-value (Frailty index) |
|---------------|--------|-------------------------|-------------------------------|------------------------|-----------------------------|
| CD27- IgD-    | male   | \(-0.601\)              | \(0.003\)                     | \(0.616\)              | \(0.002\)                   |
|               | female | \(-0.274\)              | \(0.091\)                     | \(0.157\)              | \(0.34\)                    |
| CD27- IgD+    | male   | \(0.180\)               | \(0.423\)                     | \(-0.387\)             | \(0.076\)                   |
|               | female | \(0.332\)               | \(0.039\)                     | \(-0.181\)             | \(0.27\)                    |
| CD27+ IgD+    | male   | \(0.339\)               | \(0.123\)                     | \(-0.148\)             | \(0.512\)                   |
|               | female | \(-0.173\)              | \(0.293\)                     | \(-0.113\)             | \(0.492\)                   |
| CD27+ IgD-    | male   | \(0.358\)               | \(0.102\)                     | \(-0.036\)             | \(0.874\)                   |
|               | female | \(-0.256\)              | \(0.116\)                     | \(-0.003\)             | \(0.983\)                   |

Correlation coefficient and significance of statistically significant associations are indicated in boldface.

Fig. 4 Distribution of CD19+ B cell subpopulations in nonagenarian individuals categorized with frailty index. a Nonagenarian males. b Nonagenarian females. Error bars represent 95% confidence interval.
responsiveness to it, might be involved in the observed gender difference. Thirdly, it has been shown that the frailty index is gender-dependent to a certain extent, i.e. it is somewhat higher in females than in males of the same age [19] and the clinical consequences of its increase are different in males and females [20]. It is possible that these differences are due to the differences in the inflammatory response, or the causality could be reverse, i.e. the pathogenic changes associated with the advancing frailty would activate inflammation in a gender-specific manner.

As CD27- IgD- B cells seem to be very potent activators of inflammation, even associating with adverse aging-associated effects, it is tempting to speculate that they could be a target for anti-aging therapies. In fact, Moura et al. [21] have recently shown that the increased number of CD27- IgD- cells in rheumatoid arthritis patients can be reduced back to normal levels with anti-TNF or anti-IL6 receptor antibodies.

Conclusion
We observed that CD27- IgD- B cell subset demonstrates a strong pro-inflammatory effect in nonagenarian males, which significantly associates with the decline of the bodily functions. As CD27- IgD- B cells seem to contribute to inflammation and its adverse effects, they might be an attractive target for anti-aging therapies.

Abbreviations
FBS: Fetal bovine serum; IgD: Immunoglobulin D; IL-6: Interleukin 6; IL-8: Interleukin 8; MMSE: Mini-mental state examination; PBMC: Peripheral blood mononuclear cells; PBS: Phosphate-buffered saline; SASP: Senescence –associated secretory phenotype; TNF: Tumor necrosis factor

Acknowledgements
The authors acknowledge the Tampere facility of Flow Cytometry for their service.

Authors’ contributions
TN contributed to purification of the PBMCs, performed data analysis, co-wrote the paper. AA contributed to data analysis. LK contributed to designing flow cytometric experiments, performed data analysis, and supervised the research. All authors read and approved the final manuscript.

Funding
This work was financially supported by the Competitive State Research Financing of the Expert Responsibility area of Tampere University Hospital (MH), Tampere Tuberculosis Foundation (MH and IJ), Academy of Finland (IJ: Grants 2501308481 and 25013124041), Competitive State Research Financing of the Expert Responsibility area of Fimlab Laboratories (IJ), Grant X51409) and City of Tampere Science Foundation (LK).

Availability of data and materials
Data is available from the corresponding author on reasonable request.

Ethics approval and consent to participate
The study protocol was approved by the ethics committee of the city of Tampere (1592/403/1996) and the study was conducted according to the principles expressed in the declaration of Helsinki. The study participants provided their written informed consent.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1Faculty of Medicine and Health Technology, Tampere University, FI-33014 Tampere, Finland. 2Faculty of Social Sciences, Tampere University, Tampere, Finland. 3Gerontology Research Center, Tampere University, Tampere, Finland. 4Science Centre, Pirkanmaa Hospital District, Tampere, Finland. 5Department of Clinical Microbiology, Fimlab Laboratories, Tampere, Finland.

Received: 25 March 2019 Accepted: 2 August 2019
Published online: 13 August 2019

References
1. Pawelec G. Age and immunity: what is “immunosenescence”? Exp Gerontol. 2018;105:4–9.
2. Nikolich-Zugich J. The twilight of immunity: emerging concepts in aging of the immune system. Nat Immunol. 2018;19(1):10–9.
3. Franceschi C, Garagnani P, Parini P, Giuliani C, Santoro A. Inflammaging: a new immune-metabolic viewpoint for age-related diseases. Nat Rev Endocrinol. 2018;14(10):576–90.
4. Fulop T, Witkowsi JM, Olivieri F, Larbi A. The integration of inflammaging in age-related diseases. Semin Immunol. 2018;40:17–35.
5. Blomberg BB, Frasca D. Age effects on mouse and human B cells. Immunol Res. 2013;57(1–3):354–60.
6. Frasca D, Diaz A, Romero M, Blomberg BB. Human peripheral late/exhausted memory B cells express a senescent-associated secretory phenotype and preferentially utilize metabolic signaling pathways. Exp Gerontol. 2017;87(Pt A):113–20.
7. Wei W, Ji S. Cellular senescence: molecular mechanisms and pathogenicity. J Cell Physiol. 2018;233(12):9121–35.
8. Frasca D. Senescent B cells in aging and age-related diseases: their role in the regulation of antibody responses. Exp Gerontol. 2018;107:55–8.
9. Goebeler S, Jylha M, Hervonen A. Medical history, cognitive status and mobility at the age of 90. A population-based study in Tampere, Finland. Aging Clin Exp Res. 2003;15(2):154–61.
10. Jylhava J, Nevalainen T, Marttila S, Jylha M, Hervonen A, Hurme M. Characterization of the role of distinct plasma cell-free DNA species in age-associated inflammation and frailty. Aging Cell. 2013;12(3):388–97.
11. Marttila S, Kananen L, Hayrynen S, Jylhava J, Nevalainen T, Hervonen A, et al. Ageing-associated changes in the human DNA methylome: genomic locations and effects on gene expression. BMC Genomics. 2015;16:179–015-1381-z.
12. Taimen K, Hurme M, Hervonen A, Luukkaala T, Jylha M. Inflammatory markers and physical performance among nonagenarians. J Gerontol A Biol Sci Med Sci. 2010;65(6):658–63.
13. Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Grotti Diener J, et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci. 2001;56(3):M146–56.
14. Grubeck-Loebenstein B, Della Bella S, Iorio AM, Michel JP, Pawelec G, Solana R. Immunosenescence and vaccine failure in the elderly. Aging Clin Exp Res. 2009;21(3):201–9.
15. Gallender LA, Carroll EC, Beal RWJ, Chambers ES, Nourshargh S, Akbar AN, et al. Human CD8(+) EMRA T cells display a senescence-associated secretory phenotype regulated by p38 MAPK. Aging Cell. 2018;17(1). https://doi.org/10.1111/acel.12675. Epub 2017 Oct 12.
16. Collerton J, Martin-Ruiz C, Davies K, Hilkens CM, Issacs J, Kolenda C, et al. Frailty and the role of inflammation, immunosenescence and cellular aging in the very old: cross-sectional findings from the Newcastle 85+ study. Mech Ageing Dev. 2012;133(6):456–66.
17. Nevalainen T, Kananen L, Marttila S, Jylha M, Hervonen A, Hurme M, et al. Transcriptomic and epigenetic analyses reveal a gender difference in aging-associated inflammation: the vitality 90+ study. Age (Dordr). 2015;37(4):9814–015-9814-9. Epub 2015 Jul 19.
18. Wang J, Leung KS, Chow SK, Cheung WH. Inflammation and age-associated skeletal muscle deterioration (sarcopenia). J Orthop Translat. 2017;10:94–101.
19. Williams DM, Jylhava J, Pedersen NL, Hagg S. A frailty index for UK biobank participants. J Gerontol A Biol Sci Med Sci. 2019;74(4):582–7.
20. Jiang M, Foebel AD, Kuja-Halkola R, Karlsson I, Pedersen NL, Hagg S, et al. Frailty index as a predictor of all-cause and cause-specific mortality in a Swedish population-based cohort. Aging (Albany NY). 2017;9(12):2629–46.
21. Moura RA, Quaresma C, Vieira AR, Goncalves MJ, Polido-Pereira J, Romao VC, et al. B-cell phenotype and IgD-CD27- memory B cells are affected by TNF-inhibitors and tocilizumab treatment in rheumatoid arthritis. PLoS One. 2017;12(9):e0182927.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.